Design and Development of a Macrocyclic Series Targeting Phosphoinositide 3-Kinase δ
A macrocyclization approach has been explored on a series of benzoxazine phosphoinositide 3-kinase delta inhibitors, resulting in compounds with improved potency, permeability, and in vivo clearance while maintaining good solubility. The thermodynamics of binding was explored via surface plasmon res...
Uloženo v:
| Vydáno v: | ACS medicinal chemistry letters Ročník 11; číslo 7; s. 1386 - 1391 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
WASHINGTON
Amer Chemical Soc
09.07.2020
|
| Témata: | |
| ISSN: | 1948-5875, 1948-5875 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | A macrocyclization approach has been explored on a series of benzoxazine phosphoinositide 3-kinase delta inhibitors, resulting in compounds with improved potency, permeability, and in vivo clearance while maintaining good solubility. The thermodynamics of binding was explored via surface plasmon resonance, and the binding of lead macrocycle 19 was found to be almost exclusively entropically driven compared with progenitor 18, which demonstrated both enthalpic and entropic contributions. The pharmacokinetics of macrocycle 19 was also explored in vivo, where it showed reduced clearance when compared with the progenitor 18. This work adds to the growing body of evidence that macrocyclization could provide an alternative and complementary approach to the design of small-molecule inhibitors, with the potential to deliver differentiated properties. |
|---|---|
| AbstractList | A macrocyclization approach has been explored on a series of benzoxazine phosphoinositide 3-kinase delta inhibitors, resulting in compounds with improved potency, permeability, and in vivo clearance while maintaining good solubility. The thermodynamics of binding was explored via surface plasmon resonance, and the binding of lead macrocycle 19 was found to be almost exclusively entropically driven compared with progenitor 18, which demonstrated both enthalpic and entropic contributions. The pharmacokinetics of macrocycle 19 was also explored in vivo, where it showed reduced clearance when compared with the progenitor 18. This work adds to the growing body of evidence that macrocyclization could provide an alternative and complementary approach to the design of small-molecule inhibitors, with the potential to deliver differentiated properties. A macrocyclization approach has been explored on a series of benzoxazine phosphoinositide 3-kinase δ inhibitors, resulting in compounds with improved potency, permeability, and in vivo clearance while maintaining good solubility. The thermodynamics of binding was explored via surface plasmon resonance, and the binding of lead macrocycle 19 was found to be almost exclusively entropically driven compared with progenitor 18, which demonstrated both enthalpic and entropic contributions. The pharmacokinetics of macrocycle 19 was also explored in vivo, where it showed reduced clearance when compared with the progenitor 18. This work adds to the growing body of evidence that macrocyclization could provide an alternative and complementary approach to the design of small-molecule inhibitors, with the potential to deliver differentiated properties.A macrocyclization approach has been explored on a series of benzoxazine phosphoinositide 3-kinase δ inhibitors, resulting in compounds with improved potency, permeability, and in vivo clearance while maintaining good solubility. The thermodynamics of binding was explored via surface plasmon resonance, and the binding of lead macrocycle 19 was found to be almost exclusively entropically driven compared with progenitor 18, which demonstrated both enthalpic and entropic contributions. The pharmacokinetics of macrocycle 19 was also explored in vivo, where it showed reduced clearance when compared with the progenitor 18. This work adds to the growing body of evidence that macrocyclization could provide an alternative and complementary approach to the design of small-molecule inhibitors, with the potential to deliver differentiated properties. |
| Author | Spencer, Jonathan A. Chung, Chun-Wa Convery, Maire A. Rowedder, James E. Edwards, Christopher D. Rowland, Paul Jamieson, Craig Mallett, David N. Hardy, Charlotte J. Baldwin, Ian R. Thomas, Daniel A. Barton, Nick |
| Author_xml | – sequence: 1 givenname: Jonathan A. surname: Spencer fullname: Spencer, Jonathan A. organization: GSK Med Res Ctr, Stevenage SG1 2NY, Herts, England – sequence: 2 givenname: Ian R. surname: Baldwin fullname: Baldwin, Ian R. organization: GSK Med Res Ctr, Stevenage SG1 2NY, Herts, England – sequence: 3 givenname: Nick surname: Barton fullname: Barton, Nick organization: GSK Med Res Ctr, Stevenage SG1 2NY, Herts, England – sequence: 4 givenname: Chun-Wa orcidid: 0000-0002-2480-3110 surname: Chung fullname: Chung, Chun-Wa organization: GSK Med Res Ctr, Stevenage SG1 2NY, Herts, England – sequence: 5 givenname: Maire A. surname: Convery fullname: Convery, Maire A. organization: GSK Med Res Ctr, Stevenage SG1 2NY, Herts, England – sequence: 6 givenname: Christopher D. surname: Edwards fullname: Edwards, Christopher D. organization: GSK Med Res Ctr, Stevenage SG1 2NY, Herts, England – sequence: 7 givenname: Craig orcidid: 0000-0002-6567-8272 surname: Jamieson fullname: Jamieson, Craig organization: Univ Strathclyde, Dept Pure & Appl Chem, Glasgow G1 1XL, Lanark, Scotland – sequence: 8 givenname: David N. surname: Mallett fullname: Mallett, David N. organization: GSK Med Res Ctr, Stevenage SG1 2NY, Herts, England – sequence: 9 givenname: James E. surname: Rowedder fullname: Rowedder, James E. organization: GSK Med Res Ctr, Stevenage SG1 2NY, Herts, England – sequence: 10 givenname: Paul surname: Rowland fullname: Rowland, Paul organization: GSK Med Res Ctr, Stevenage SG1 2NY, Herts, England – sequence: 11 givenname: Daniel A. orcidid: 0000-0002-5177-1900 surname: Thomas fullname: Thomas, Daniel A. organization: GSK Med Res Ctr, Stevenage SG1 2NY, Herts, England – sequence: 12 givenname: Charlotte J. orcidid: 0000-0003-1195-7628 surname: Hardy fullname: Hardy, Charlotte J. email: charlotte.hardy@crl.com organization: GSK Med Res Ctr, Stevenage SG1 2NY, Herts, England |
| BookMark | eNqN0EtOwzAUBVALgegHtoA8REIp_qcZopafKAKJdlw5znNrlNgldkHdF-tgTQSVAUPe5N7B0R28ATr0wQNCZ5SMKGH0UpvYQGXW0NSQ0ogYQoiiB6hPCzHO5DiXh396Dw1ifO1EkefkGPU4U7miQvTRYgrRrTzWvsJTeIc6bBrwCQeLNX7Upg1mZ2pn8Au0DiKe63YFyfkVfl6HuFkH50N0yVWAefbgvI6Avz5P0JHVdYTT3xyixc31fHKXzZ5u7ydXs0wLLlImKhCGl0VlTcFKKe2YW2molWUliZJcFkrx0loueFHKUnGjpJJMEqAVYxVlQ3S-39204W0LMS0bFw3UtfYQtnHJBBNFwRRlHb3Y0w8og43GgTew3LSu0e1u2X1PSpKrnPyc6vT4_3rikk4u-EnY-sS-ASSefT8 |
| CitedBy_id | crossref_primary_10_1021_acs_jmedchem_4c02886 crossref_primary_10_1038_s41597_024_04302_z crossref_primary_10_1080_1062936X_2023_2181392 crossref_primary_10_1016_j_ejmech_2024_116501 crossref_primary_10_1016_j_bioorg_2025_108190 crossref_primary_10_15212_AMM_2024_0070 crossref_primary_10_1038_s41594_024_01265_y |
| Cites_doi | 10.5599/admet.5.1.373 10.1021/jm400887j 10.1039/c0sc00331j 10.1021/jm4008642 10.1056/NEJMoa1315226 10.1021/jm500261q 10.1038/nrd2590 10.1038/nrg1879 10.1110/ps.4330102 10.1021/jm060884i 10.1021/ml100142y 10.1124/pr.110.004051 10.1021/acs.jmedchem.7b00359 10.1002/anie.200600844 10.1021/jm200326p 10.4155/FMC.11.12 10.1021/acs.jmedchem.5b00767 10.1164/rccm.200906-0937OC |
| ContentType | Journal Article |
| Copyright | Copyright © 2020 American Chemical Society. |
| Copyright_xml | – notice: Copyright © 2020 American Chemical Society. |
| DBID | 17B 1KM AOWDO BLEPL DTL EGQ 7X8 |
| DOI | 10.1021/acsmedchemlett.0c00061 |
| DatabaseName | Web of Knowledge Index Chemicus Web of Science - Science Citation Index Expanded - 2020 Web of Science Core Collection Science Citation Index Expanded Web of Science Primary (SCIE, SSCI & AHCI) MEDLINE - Academic |
| DatabaseTitle | Web of Science MEDLINE - Academic |
| DatabaseTitleList | Web of Science MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: 1KM name: Index Chemicus url: https://www.webofscience.com/wos/woscc/search-with-editions?editions=WOS.IC sourceTypes: Enrichment Source Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1948-5875 |
| EndPage | 1391 |
| ExternalDocumentID | 000550767000006 |
| GrantInformation_xml | – fundername: EPSRC; UK Research & Innovation (UKRI); Engineering & Physical Sciences Research Council (EPSRC) grantid: EP/S035990/1 |
| GroupedDBID | --- 17B 1KM 53G 55A 5VS 7~N AABXI ABBLG ABJNI ABLBI ABMVS ABQRX ABUCX ACGFO ACGFS ACS ADBBV ADHLV AEESW AENEX AFEFF AHGAQ ALMA_UNASSIGNED_HOLDINGS AOIJS AQSVZ BAANH BAWUL BLEPL CUPRZ DIK DTL EBS ED~ F5P GGK GNL GROUPED_WOS_WEB_OF_SCIENCE GX1 HYE IH9 JG~ OK1 P2P RNS ROL RPM UI2 VF5 VG9 W1F XKZ 7X8 |
| ID | FETCH-LOGICAL-a434t-4de4c3b9dfc92b55f83f5c1f5bd5065359663bff3439b5b63c6565250e1d22d12 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 8 |
| ISICitedReferencesURI | https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=CitingArticles&UT=000550767000006 |
| ISSN | 1948-5875 |
| IngestDate | Thu Jul 10 20:05:46 EDT 2025 Wed Nov 26 07:25:52 EST 2025 Fri Dec 05 23:00:47 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | Thermodynamics POTENT Lipid kinase OPTIMIZATION PI3K delta INHIBITORS BINDING DISCOVERY Macrocycle |
| Language | English |
| LinkModel | DirectLink |
| LogoURL | https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg |
| MergedId | FETCHMERGED-LOGICAL-a434t-4de4c3b9dfc92b55f83f5c1f5bd5065359663bff3439b5b63c6565250e1d22d12 |
| Notes | UKRI ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-5177-1900 0000-0002-2480-3110 0000-0002-6567-8272 0000-0003-1195-7628 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/7357223 |
| PMID | 32676144 |
| PQID | 2424992612 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | webofscience_primary_000550767000006 proquest_miscellaneous_2424992612 webofscience_primary_000550767000006CitationCount |
| PublicationCentury | 2000 |
| PublicationDate | 2020-07-09 |
| PublicationDateYYYYMMDD | 2020-07-09 |
| PublicationDate_xml | – month: 07 year: 2020 text: 2020-07-09 day: 09 |
| PublicationDecade | 2020 |
| PublicationPlace | WASHINGTON |
| PublicationPlace_xml | – name: WASHINGTON |
| PublicationTitle | ACS medicinal chemistry letters |
| PublicationTitleAbbrev | ACS MED CHEM LETT |
| PublicationYear | 2020 |
| Publisher | Amer Chemical Soc |
| Publisher_xml | – name: Amer Chemical Soc |
| References | McNamara, CR (WOS:000290595800011) 2011; 3 McCoull, W (WOS:000402498200021) 2017; 60 DeLorbe, JE (WOS:000284203100016) 2010; 1 Finan, PM (WOS:000221132800050) 2004; 32 Driggers, EM (WOS:000257268200015) 2008; 7 Mann, A (WOS:000311276600020) 2008 Foster, JG (WOS:000309551500008) 2012; 64 (000550767000006.1) 2017 Stachel, SJ (WOS:000241192400003) 2006; 49 Sutherland, H (WOS:000188444800019) 1936; 58 Giordanetto, F (WOS:000330252500002) 2014; 57 Engelman, JA (WOS:000239118400013) 2006; 7 Surry, DS (WOS:000285009500003) 2011; 2 Stepan, AF (WOS:000330097400035) 2013; 56 Valko, K (WOS:000447339300003) 2017; 5 Down, K (WOS:000361921800021) 2015; 58 MOREE, WJ (WOS:A1993KL18700016) 1993; 49 de Mol, NJ (WOS:000226881300012) 2005; 48 To, Y (WOS:000282673200009) 2010; 182 William, AD (WOS:000292479600026) 2011; 54 Johnson, TW (WOS:000337336600023) 2014; 57 Furman, RR (WOS:000332689100007) 2014; 370 Day, YSN (WOS:000175141900003) 2002; 11 Benfield, AP (WOS:000241637500009) 2006; 45 |
| References_xml | – volume: 5 start-page: 14 year: 2017 ident: WOS:000447339300003 article-title: In vitro membrane binding and protein binding (IAM MB/PB technology) to estimate in vivo distribution: applications in early drug discovery publication-title: ADMET AND DMPK doi: 10.5599/admet.5.1.373 – volume: 57 start-page: 278 year: 2014 ident: WOS:000330252500002 article-title: Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties? publication-title: JOURNAL OF MEDICINAL CHEMISTRY doi: 10.1021/jm400887j – volume: 58 start-page: 62 year: 1936 ident: WOS:000188444800019 article-title: Anomalous mutarotation of salts of Reychler's acid.: IV.: Comparison of 2-(N-phenylketimine)-d-camphane-10-sulfonic acid with d-camphor-10-sulfonanilide publication-title: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY – volume: 2 start-page: 27 year: 2011 ident: WOS:000285009500003 article-title: Dialkylbiaryl phosphines in Pd-catalyzed amination: a user's guide publication-title: CHEMICAL SCIENCE doi: 10.1039/c0sc00331j – volume: 56 start-page: 6985 year: 2013 ident: WOS:000330097400035 article-title: Evaluating the Differences in Cycloalkyl Ether Metabolism Using the Design Parameter "Lipophilic Metabolism Efficiency" (LipMetE) and a Matched Molecular Pairs Analysis publication-title: JOURNAL OF MEDICINAL CHEMISTRY doi: 10.1021/jm4008642 – volume: 370 start-page: 997 year: 2014 ident: WOS:000332689100007 article-title: Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia publication-title: NEW ENGLAND JOURNAL OF MEDICINE doi: 10.1056/NEJMoa1315226 – volume: 48 start-page: 753 year: 2005 ident: WOS:000226881300012 article-title: Surface plasmon resonance thermodynamic and kinetic analysis as a strategic tool in drug design. Distinct ways for Phosphopeptides to plug into Src and Grb2 SH2 domain publication-title: JOURNAL OF MEDICINAL CHEMISTRY – volume: 57 start-page: 4720 year: 2014 ident: WOS:000337336600023 article-title: Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations publication-title: JOURNAL OF MEDICINAL CHEMISTRY doi: 10.1021/jm500261q – start-page: 363 year: 2008 ident: WOS:000311276600020 article-title: Conformational Restriction and/or Steric Hindrance in Medicinal Chemistry publication-title: PRACTICE OF MEDICINAL CHEMISTRY, 3RD EDITION – volume: 49 start-page: 1133 year: 1993 ident: WOS:A1993KL18700016 article-title: SYNTHESIS OF PEPTIDES CONTAINING A SULFINAMIDE OR A SULFONAMIDE TRANSITION-STATE ISOSTERE publication-title: TETRAHEDRON – volume: 7 start-page: 608 year: 2008 ident: WOS:000257268200015 article-title: The exploration of macrocycles for drug discovery - an underexploited structural class publication-title: NATURE REVIEWS DRUG DISCOVERY doi: 10.1038/nrd2590 – volume: 7 start-page: 606 year: 2006 ident: WOS:000239118400013 article-title: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism publication-title: NATURE REVIEWS GENETICS doi: 10.1038/nrg1879 – year: 2017 ident: 000550767000006.1 article-title: Use of Inhibitors of the Activity or Function of PI3K for the Treatment of Primary Sjoegren's Syndrome – volume: 11 start-page: 1017 year: 2002 ident: WOS:000175141900003 article-title: Direct comparison of binding equilibrium, thermodynamic, and rate constants determined by surface- and solution-based biophysical methods publication-title: PROTEIN SCIENCE doi: 10.1110/ps.4330102 – volume: 32 start-page: 378 year: 2004 ident: WOS:000221132800050 article-title: PI 3-kinase inhibition: a therapeutic target for respiratory disease publication-title: BIOCHEMICAL SOCIETY TRANSACTIONS – volume: 49 start-page: 6147 year: 2006 ident: WOS:000241192400003 article-title: Macrocyclic inhibitors of β-secretase:: Functional activity in an animal model publication-title: JOURNAL OF MEDICINAL CHEMISTRY doi: 10.1021/jm060884i – volume: 1 start-page: 448 year: 2010 ident: WOS:000284203100016 article-title: Thermodynamic and Structural Effects of Macrocyclic Constraints in Protein-Ligand Interactions publication-title: ACS MEDICINAL CHEMISTRY LETTERS doi: 10.1021/ml100142y – volume: 64 start-page: 1027 year: 2012 ident: WOS:000309551500008 article-title: Inhibition of PI3K Signaling Spurs New Therapeutic Opportunities in Inflammatory/Autoimmune Diseases and Hematological Malignancies publication-title: PHARMACOLOGICAL REVIEWS doi: 10.1124/pr.110.004051 – volume: 60 start-page: 4386 year: 2017 ident: WOS:000402498200021 article-title: Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors publication-title: JOURNAL OF MEDICINAL CHEMISTRY doi: 10.1021/acs.jmedchem.7b00359 – volume: 45 start-page: 6830 year: 2006 ident: WOS:000241637500009 article-title: Ligand preorganization may be accompanied by entropic penalties in protein-ligand interactions publication-title: ANGEWANDTE CHEMIE-INTERNATIONAL EDITION doi: 10.1002/anie.200600844 – volume: 54 start-page: 4638 year: 2011 ident: WOS:000292479600026 article-title: Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma publication-title: JOURNAL OF MEDICINAL CHEMISTRY doi: 10.1021/jm200326p – volume: 3 start-page: 549 year: 2011 ident: WOS:000290595800011 article-title: Small-molecule inhibitors of the PI3K signaling network publication-title: FUTURE MEDICINAL CHEMISTRY doi: 10.4155/FMC.11.12 – volume: 58 start-page: 7381 year: 2015 ident: WOS:000361921800021 article-title: Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease publication-title: JOURNAL OF MEDICINAL CHEMISTRY doi: 10.1021/acs.jmedchem.5b00767 – volume: 182 start-page: 897 year: 2010 ident: WOS:000282673200009 article-title: Targeting Phosphoinositide-3-Kinase-δ with Theophylline Reverses Corticosteroid Insensitivity in Chronic Obstructive Pulmonary Disease publication-title: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE doi: 10.1164/rccm.200906-0937OC |
| SSID | ssj0069770 |
| Score | 2.2618353 |
| Snippet | A macrocyclization approach has been explored on a series of benzoxazine phosphoinositide 3-kinase delta inhibitors, resulting in compounds with improved... A macrocyclization approach has been explored on a series of benzoxazine phosphoinositide 3-kinase δ inhibitors, resulting in compounds with improved potency,... |
| Source | Web of Science |
| SourceID | proquest webofscience |
| SourceType | Aggregation Database Enrichment Source Index Database |
| StartPage | 1386 |
| SubjectTerms | Chemistry, Medicinal Life Sciences & Biomedicine Pharmacology & Pharmacy Science & Technology |
| Title | Design and Development of a Macrocyclic Series Targeting Phosphoinositide 3-Kinase δ |
| URI | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=FullRecord&UT=000550767000006 https://www.proquest.com/docview/2424992612 |
| Volume | 11 |
| WOS | 000550767000006 |
| WOSCitedRecordID | wos000550767000006 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF58Hbz4FuujrCA9NZp9Jc1JpCqCKD200FvZJxY0qaYK_V_-Dn-TO9vUKngQvIckzA4z38588w1CJ5xQKahMI-XBaMRVSiKllY249dmCJC6lOg7LJtL7-1a_n3WqgltZ0SpnMTEEalNoqJGfwRhDloHg1fnoOYKtUdBdrVZoLKJl5qEMULrS_lcXIfHYJgxEZhymi1IxmxCm5EzqEgiQD_bJm2d8GuuQzH_AzF8SUUg61-v__d0NtFbBTXwx9Y9NtGDzLdToTPWqJ03cnY9flU3cwJ25kvVkG_UuA78Dy9zgb-wiXDgs8Z30MVxP9ONQY6ix2RJ3A63cJ0P_nqIcPRTDPHDCjMUM9hT7jIk_3ndQ7_qq276Jqj0MkeSMjyNuLNdMZcbpjCohXIs5oYkTygiQthX-ysSUc8yDGyVUwrQHidAutcRQagjdRUt5kds9IFIpk6SGk1inPJO2xamjiYxtKzY2Zq6GjmfmHHg_h-aFzG3xWg7mBq2hk-8nMxhNZTmgjQ7ibDB3BIdZQ-Qvj7UrKXSQABjv_-HzB2iVwp0bSrzZIVp2PkzYI7Si38bD8qXuIfrtXT344SchQud_ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Design+and+Development+of+a+Macrocyclic+Series+Targeting+Phosphoinositide+3-Kinase+%CE%B4&rft.jtitle=ACS+medicinal+chemistry+letters&rft.au=Spencer%2C+Jonathan+A.&rft.au=Baldwin%2C+Ian+R.&rft.au=Barton%2C+Nick&rft.au=Chung%2C+Chun-Wa&rft.date=2020-07-09&rft.pub=Amer+Chemical+Soc&rft.issn=1948-5875&rft.eissn=1948-5875&rft.volume=11&rft.issue=7&rft.spage=1386&rft.epage=1391&rft_id=info:doi/10.1021%2Facsmedchemlett.0c00061&rft_id=info%3Apmid%2F32676144&rft_id=info%3Apmid%2F32676144&rft.externalDBID=n%2Fa&rft.externalDocID=000550767000006 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1948-5875&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1948-5875&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1948-5875&client=summon |